Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

• Published in: Science (American Association for the Advancement of Science) Vol. 374; no. 6566; p. eabj9853
• Main Authors: Mateus, Jose, Dan, Jennifer M., Zhang, Zeli, Rydyznski Moderbacher, Carolyn, Lammers, Marshall, Goodwin, Benjamin, Sette, Alessandro, Crotty, Shane, Weiskopf, Daniela
• Format: Journal Article
• Language: English
• Published: United States The American Association for the Advancement of Science 22.10.2021
• Subjects: 2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; Age; Age differences; Aged; Aged, 80 and over; Antibodies; Antibodies, Viral - blood; Antiviral drugs; Between-subjects design; Binding; Blood; CD4 antigen; CD4-Positive T-Lymphocytes - immunology; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Clinical trials; Clinical Trials, Phase I as Topic; Coronaviruses; COVID-19; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Cross Reactions; Dosage; Durability; Equivalence; Feedback (Response); Helper cells; Humans; Immunity; Immunization; Immunogenicity, Vaccine; Immunologic Memory; Immunological memory; Immunology; Infections; Interferon; Longitudinal Studies; Lymphocytes; Lymphocytes T; Memory; Memory cells; Middle Aged; mRNA; mRNA vaccines; Neutralizing; Patients; Questions; Respiratory diseases; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; Vaccination; Vaccines; Viral diseases; Young Adult; γ-Interferon

Low-dose messenger RNA (mRNA) vaccines potentially allow health providers to administer more doses from a limited vaccine supply and can be less reactogenic. Whether low-dose COVID-19 mRNA vaccines generate immune responses comparable to currently approved doses remains an open question, however. Ma...